1. Solimando, AG, Annese, T, Tamma, R, et al. New insights into diffuse large B-cell lymphoma pathobiology. Cancers (Basel) 2020; 12: 1–22.
Google Scholar | Crossref2. National Cancer Institute . SEER cancer stat facts: diffuse large B-cell lymphoma [Internet], https://seer.cancer.gov/statfacts/html/dlbcl.html (2019, accessed 4 January 2021).
Google Scholar3. Coiffier, B, Ementine Sarkozy, C. Diffuse large B-cell lymphoma: R-CHOP failure – what to do? Hematol Am Soc Hematol Educ Progr 2016; 2016: 366–378.
Google Scholar | Crossref | Medline4. Crump, M, Neelapu, SS, Farooq, U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800–1808.
Google Scholar | Crossref | Medline5. Zinzani, PL, Pellegrini, C, Gandolfi, L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462–466.
Google Scholar | Crossref | Medline6. Wang, K, Wei, G, Liu, D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1: 36.
Google Scholar | Crossref | Medline7. Fujimoto, M, Fujimoto, Y, Poe, JC, et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000; 13: 47–57.
Google Scholar | Crossref | Medline8. Hojer, C, Frankenberger, S, Strobl, LJ, et al. B-cell expansion and lymphomagenesis induced by chronic CD40 signaling is strictly dependent on CD19. Cancer Res 2014; 74: 4318–4328.
Google Scholar | Crossref | Medline9. Chung, EY, Psathas, JN, Yu, D, et al. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012; 122: 2257–2266.
Google Scholar | Crossref | Medline10. Makita, S, Tobinai, K. Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphoma. Ann Oncol 2018; 29: 1086–1089.
Google Scholar | Crossref | Medline11. Abramson, JS, Ghosh, N, Smith, SM. ADCs, BiTEs, CARs, and small molecules: a new era of targeted therapy in non-Hodgkin lymphoma. Am Soc Clin Oncol Educ Book 2020; 40: 302–313.
Google Scholar | Crossref12. Watkins, MP, Bartlett, NL. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. Expert Opin Investig Drugs 2018; 27: 601–611.
Google Scholar | Crossref | Medline13. Hoy, SM . Tafasitamab: first approval. Drugs 2020; 80: 1731–1737.
Google Scholar | Crossref | Medline14. Thapa, B, Caimi, PF, Ardeshna, KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv 2020; 4: 3850–3852.
Google Scholar | Crossref | Medline15. Coiffier, B, Thieblemont, C, de Guibert, S, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol 2016; 173: 722–730.
Google Scholar | Crossref | Medline16. Katz, BZ, Herishanu, Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma 2014; 55: 999–1006.
Google Scholar | Crossref | Medline17. Lazar, GA, Dang, W, Karki, S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103: 4005–4010.
Google Scholar | Crossref | Medline | ISI18. Horton, HM, Bernett, MJ, Pong, E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049–8057.
Google Scholar | Crossref | Medline19. Awan, FT, Lapalombella, R, Trotta, R, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115: 1204–1213.
Google Scholar | Crossref | Medline20. Rafiq, S, Cheney, C, Mo, X, et al. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52-and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 2012; 26: 1720–1722.
Google Scholar | Crossref | Medline21. Kellner, C, Zhukovsky, EA, Pötzke, A, et al. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia 2013; 27: 1595–1598.
Google Scholar | Crossref | Medline22. Woyach, JA, Awan, F, Flinn, IW, et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood 2014; 124: 3553–3560.
Google Scholar | Crossref | Medline23. Jurczak, W, Zinzani, PL, Hess, G, et al. A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma: long-term follow-up, final analysis. Blood 2019; 134: 4078.
Google Scholar | Crossref24. Jurczak, W, Zinzani, PL, Gaidano, G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Ann Oncol 2018; 29: 1266–1272.
Google Scholar | Crossref | Medline25. Batoo, SA, Hernandez-Ilizaliturri, FJ. The emerging role of lenalidomide in the management of lymphoid malignancies. Ther Adv Hematol 2011; 2: 45–53.
Google Scholar | SAGE Journals26. Gribben, JG, Fowler, N, Morschhauser, F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 2015; 33: 2803–2811.
Google Scholar | Crossref | Medline27. Witzig, TE, Nowakowski, GS, Habermann, TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 2015; 26: 1667–1677.
Google Scholar | Crossref | Medline28. Wang, M, Fowler, N, Wagner-Bartak, N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27: 1902–1909.
Google Scholar | Crossref | Medline29. Castellino, A, Chiappella, A, LaPlant, BR, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J 2018; 8: 108.
Google Scholar | Crossref | Medline30. Vitolo, U, Witzig, TE, Gascoyne, RD, et al. ROBUST: first report of phase III randomized study of lenalidomide/R-CHOP (R2 -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol 2019; 37: 36–37.
Google Scholar | Crossref31. Thieblemont, C, Tilly, H, Gomes, da, Silva, M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2017; 35: 2473–2481.
Google Scholar | Crossref | Medline32. Vo, DN, Alexia, C, Allende-Vega, N, et al. NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. Oncoimmunology 2017; 7: e1409322.
Google Scholar | Crossref | Medline33. Salles, G, Duell, J, González Barca, E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020; 21: 978–988.
Google Scholar | Crossref | Medline34. Plonquet, A, Haioun, C, Jais, JP, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 2007; 18: 1209–1215.
Google Scholar | Crossref | Medline35. Kim, JK, Chung, JS, Shin, HJ, et al. Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood Res 2014; 49: 162–169.
Google Scholar | Crossref | Medline36. Klanova, M, Oestergaard, MZ, Trneny, M, et al. Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large b-cell lymphoma patients treated with immunochemotherapy. Clin Cancer Res 2019; 25: 4632–4643.
Google Scholar | Crossref37. Danielou-Lazareth, A, Henry, G, Geromin, D, et al. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. Eur J Immunol 2013; 43: 1383–1388.
Google Scholar | Crossref | Medline38. Sarkar, S, Sabhachandani, P, Ravi, D, et al. Dynamic analysis of human natural killer cell response at single-cell resolution in B-Cell Non-Hodgkin Lymphoma. Front Immunol 2017; 8: 1–13.
Google Scholar | Crossref | Medline39. Tamma, R, Ranieri, G, Ingravallo, G, et al. Inflammatory cells in diffuse large B cell lymphoma. J Clin Med 2020; 9: 2418.
Google Scholar | Crossref | Medline40. Zhou, H, Zheng, C, Huang, DS. A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma. PeerJ 2020; 8: 1–18.
Google Scholar | Crossref41. Burke, JM, André, M, Cheson, BD, et al. A phase Ib, open-label, randomized study to assess safety and preliminary efficacy of tafasitamab (MOR208) or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma: the first-mind trial. Blood 2019; 134: 2877.
Google Scholar | Crossref42. Maddocks, KJ, Duell, J, González-Barca, E, et al. Long-term subgroup analyses from L-mind, a phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2020; 136: 19–21.
Google Scholar | Crossref43. Salles, G, Duell, J, Gonzalez-Barca, E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. EHA Libr, p. 293691; EP1201, https://library.ehaweb.org/eha/2020/eha25th/293691/gilles.salles.long-term.outcomes.from.the.phase.ii.l-mind.study.of.tafasitamab.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dl-mind (2020, accessed 17 June 2020).
Google Scholar44. Zinzani, PL, Rodgers, T, Marino, D, et al. RE-MIND study: comparison of tafasitamab + lenalidomide (L-MIND) vs lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. Abstract S238 presented at EHA on 11-21 June 2020, p. S238, https://library.ehaweb.org/eha/2020/eha25th/295058/p.zinzani.re-mind.study.comparison.of.tafasitamab.2B.lenalidomide.28l-mind29.vs.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1766%2Aot_id%3D23235%2Amarker%3D756 (2020, accessed 17 June 2020).
Google Scholar45. Nowakowski, G, Rodgers, T, Marino, D, et al. RE-MIND study: a propensity score-based 1:1-matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. J Clin Oncol 2020; 38: abstract 8020 and poster 353.
Google Scholar | Crossref46. Wiernik, PH, Lossos, IS, Tuscano, JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26: 4952–4957.
Google Scholar | Crossref | Medline | ISI47. Witzig, TE, Vose, JM, Zinzani, PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 2011; 22: 1622–1627.
Google Scholar | Crossref | Medline | ISI48. Czuczman, MS, Trneˇný, M, Davies, A, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 2017; 23: 4127–4137.
Google Scholar | Crossref | Medline49. FDA . FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma (accessed 30 September 2020).
Google Scholar